Viking stock slides 8% following Q4 report, pipeline update
Shares of Viking Therapeutics (VKTX) slid 8% post-market after the biotech company issued its Q4 earnings report and a pipeline update. Read more here.
D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
Hosted on MSN3d
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...
Vanda stock holds Buy rating, $18 target from H.C. Wainwright
H.C. Wainwright maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ:VNDA) with a price target of $18.00, representing significant upside potential from the current price of $4.31. According to ...